Posted by Michael Rae on May 23, 2011 | Chief Science Officer's Team

Efficient, safe methods of gene therapy will be essential enabling technologies for the repair or obviation of several of the cellular and molecular lesions driving age-related disease and dysfunction. A recent paper from the Scripps Institute demonstrates a major step in this direction with the successful use of helper-dependent adenoviral vectors to rescue cells defective in lamin A, without detectable mutational side-effects.

Posted by Sarah Marr on May 4, 2011 | Founders

SENS Foundation's Year End Report for 2010, including an overview of the year from our CEO, Mike Kope; a research summary from CSO Aubrey de Grey; commentaries on our Research Center operations and our outreach activities; and a breakdown of our 2010 finances.